Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study

Rationale:

Clinical remission is the therapeutic objective in rheumatoid arthritis, as recommended by professional practice guidelines. Once this objective is achieved with subcutaneous TNF-blockers, the maintenance of such treatments - highly efficacious but expensive and potentially toxic - is debated. To date, no reliable data are available to estimate the risk - benefice ratio associated with either their maintenance or their tapering.

Objectives:

In RA patients in remission, the study aims:

• To compare RA inflammatory activity based on repeated measures of the Disease Activity Score (DAS) depending on 2 therapeutic schemes: (M) maintenance of unchanged TNF-blockers or (S) tapering of TNF-blocker doses by progressive spacing of subcutaneous injections according to a predefined algorithm;
• To estimate the cost - effectiveness ratio of TNF-blocker spacing as compared to TNF-blocker maintenance.

Inclusion criteria

• Patients aged 18 or more, diagnosed with RA according to the 1987 ACR classification criteria;
• RA treated with subcutaneous TNF-blockers (etanercept or adalimumab) at stable and standard dosage for 1 year or more, as monotherapy or associated with stable conventional DMARD;
• RA in clinical remission, defined as a stable DAS28 ≤ 2.6 for 6 months or more, without any structural damage progression on X-rays (local reading by the treating rheumatologist);

Exclusion criteria

• Treatment with steroids;
• progressing disease on X-rays during the year preceding the trial;
• surgery planed in the 18 coming months;
• pregnancy;
• on-going neoplastic disease;
• other auto-immune disorders different from RA;
• inability to speak or understand French;
• absence of signed informed consent;
• absence of medical insurance coverage.

Sample size calculation: 250 patients, 125 for each arm.

Centers: 22 inclusion centers in France.

Research duration: 3 years. Participation duration for each patient: 18 months. Inclusion period duration: 18 months (Sep 2008 - Feb 2010).

Methods:

Equivalence trial, prospective, randomized, controlled versus usual care, patients remaining blinded of the tested hypotheses.

Investigators assessing disease activity remain blind of the protocol arm. The statistical analysis will be based on a mixed linear model taking into account repeated data.

Randomization:

Computer-assisted randomization (CleanWeb software) by blocks of unequal size, stratified on inclusion centers and TNF-blocker molecule.

Primary endpoint:

RA inflammatory activity over 18 months estimated by DAS28 repeated measures.

Secondary endpoints:

• RA inflammatory activity over 18 months estimated by DAS44 repeated measures;
• Cost - Effectiveness ratio calculated as: (CostMaintenance - CostSpacing) / (EfficacyMaintenance - EfficacySpacing);
• Relapse rate over 18 months based on Kaplan Meier survival analysis;
• Functional impairment based on HAQ index;
• Health-related quality of life on SF-36;
• Utility based on EQ-5D instrument;
• Structural damage progression over 18 months assessed with the van der HEIJDE-modified Sharp score (SHS);
• Safety;
• Determinants of maintained remission or relapse after TNF-blocker injection spacing.

Research time sheet:

Clinical, biological and imaging follow-up is based on guidelines-recommended RA follow-up.

Biological work-ups specifically dedicated to the research represent 80 mL. The others are part of usual care and may be performed in non-hospital laboratories.

Expected results and perspectives:

The trial aims to test the feasibility and the risk - benefit ratio of a step-down strategy for TNF-blockers in the course of RA.

Inclusion criteria

• Patients aged 18 or more, diagnosed with RA according to the 1987 ACR classification criteria;
• RA treated with subcutaneous TNF-blockers (étanercept or adalimumab) at stable and standard dosage for 1 year or more, as monotherapy or associated with stable conventional DMARD;
• RA in clinical remission, defined as a stable DAS28 ≤ 2.6 for 6 months or more, without any structural damage progression on X-rays (local reading by the treating rheumatologist);

Exclusion criteria

• Treatment with steroids;
• progressing disease on X-rays during the year preceding the trial;
• surgery planed in the 18 coming months;
• pregnancy;
• on-going neoplastic disease;
• other auto-immune disorders different from RA;
• inability to speak or understand French;
• absence of signed informed consent;
• absence of medical insurance coverage.